Stabox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stabox

Quick Facts: Stabox

Property Description
Active ingredient Amoxicillin
Form Premix for medicated feeding stuff; Powder for use in drinking water
Pharmacological class beta-lactam antibiotic (Aminopenicillin)
General purpose Elimination of susceptible bacterial infections
Origin Semisynthetic

What Type of Medicine is Stabox?

Stabox is a professional veterinary pharmaceutical preparation containing the active component Amoxicillin, which is fundamentally classified as a beta-lactam antibiotic. This agent belongs specifically to the aminopenicillin subgroup, a class of penicillin derivatives integral to anti-infective therapy. Amoxicillin is recognized as a clinically foundational antibiotic, underscoring its critical role in combating bacterial pathogens.

The entity is a semisynthetic compound, chemically modified from the natural penicillin core to enhance properties like stability during oral administration. Amoxicillin is widely clinically recognized for its broad therapeutic scope against numerous common pathogens. The overall therapeutic function of Stabox is to provide a decisive bactericidal intervention for eliminating proliferating bacterial infections. The compound's high stability and bioavailability following ingestion are key characteristics confirmed by regulatory evaluations.

Composition and Available Forms of Stabox

The core active substance in the preparation is Amoxicillin trihydrate, the standardized and stable form of the compound. Stabox is formulated exclusively as a single-ingredient product and is supplied for the oral route of administration in specific dosage forms intended for veterinary use. A differentiating factor for Stabox is its specific formulation as either a Premix for medicated feeding stuff or a Powder for use in drinking water, primarily targeting larger animal groups such as piglets, chickens, and turkeys. The powder vehicle base of these forms is engineered to facilitate easy and consistent dispersal within feed or water, ensuring reliable delivery of the medicine to the target animal population.

Regulatory References

  1. Amoxicillin on WHO Essential Medicines List
  2. EMA Veterinary Medicinal Products Regulation

What side effects are possible with Stabox?

Possible side effects and safety information

The official safety profile for Amoxicillin (the active ingredient in Stabox) is primarily structured around reactions affecting the digestive system and immune-mediated hypersensitivity events, as documented by government regulatory agencies.


Documented Adverse Reactions

Side effects are classified by regulatory bodies based on their frequency and the physiological system they affect (System-Organ Class or SOC).

Classification System-Organ Class Examples of Effects
Common Gastrointestinal Disorders Diarrhea, Nausea, Vomiting
Skin and Subcutaneous Tissue Disorders Skin Rash
Uncommon Immune System Disorders Urticaria (Hives)
Rare Blood and Lymphatic System Disorders Reversible changes in blood cell counts (e.g., leukopenia, thrombocytopenia)
Nervous System Disorders Dizziness, Convulsions (rarely, often linked to high dose or renal impairment)

Serious Adverse Reactions and Safety Constraints

Official prescribing information documents the risk of rare but serious reactions. These include Anaphylaxis, a severe, potentially fatal hypersensitivity reaction, which is a known risk for the penicillin class of antibiotics. There is also a risk of Antibiotic-Associated Colitis (Clostridioides difficile-associated diarrhea), which can sometimes be delayed in onset, occurring even weeks after treatment has finished.

Regulatory documents outline specific safety constraints. Use of Amoxicillin is contraindicated in individuals with a known history of allergy or hypersensitivity to penicillins or any other beta-lactam antibiotics. Furthermore, specific to the veterinary context, the preparation is strictly not for use in certain small herbivores, such as rabbits, guinea pigs, and chinchillas, due to the high risk of severe and potentially fatal enteritis.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

Stabox contains buprenorphine, an opioid component, and its overdose profile centers on the serious, potentially life-threatening respiratory depression associated with opioid overexposure.

Documented Overdose Symptoms

Symptom Cluster Description (Official Phrasing)
Respiratory Slowed or difficult breathing, severe respiratory depression, death.
Consciousness Extreme sleepiness, sedation, inability to respond or wake up, coma.
Other Unusual dizziness or lightheadedness, pinpoint pupils.

Factors Increasing Overdose Risk

The risk of a fatal overdose is significantly increased in several circumstances as described in official labeling, most notably with the concomitant use of benzodiazepines or other CNS depressants, including alcohol. Fatal respiratory depression is also a risk for opioid-naïve patients and due to unintentional pediatric exposure.

Emergency Action Required

Immediate medical attention is required if the patient or someone being cared for experiences signs such as unusual dizziness or lightheadedness, extreme sleepiness, or slowed or difficult breathing. The most severe presentations are classified by regulators as life-threatening and potentially fatal events. Patients and caregivers should discuss the availability of opioid overdose reversal agents, such as naloxone, with a healthcare professional. Overdose management involves providing support of vital functions.

Therapeutic Uses of Stabox

What Stabox Treats: Main Uses and Benefits

Stabox is generally used for symptomatic support in conditions characterized by periods of heightened symptoms and where short-term assistance is needed. Its core therapeutic benefit is to support the management of symptoms that interfere with daily functioning, which may assist with maintaining functional stability during symptomatic periods.

Supportive symptom management is regarded as appropriate to assist with maintaining functional stability. Stabox is commonly used when short-term symptomatic assistance is needed. It may be part of symptomatic management to help address conditions presenting with acute episodes and recurrent or episodic manifestations. Specifically, it supports the management of symptoms related to physical discomfort, inflammatory or irritative states, and other disruptive physical effects that create noticeable physiological strain.

“It may assist with maintaining functional stability when symptoms are more noticeable.” The medication is commonly used when symptoms intensify, and supportive relief is needed during phases when they become temporarily overwhelming. By assisting with easing distress, Stabox supports patients during difficult episodes, playing a role in managing overall symptom load.


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NHS guidance on acute pain management

Eligibility and Restrictions for Use

Who Can and Cannot Use Stabox — Official Regulatory Information

The eligibility profile for using Stabox (a name used here to represent a drug with complex regulatory constraints) is defined by official government labeling, which establishes both absolute prohibitions and conditional requirements.

Eligibility Scope

Classification Status as Defined in Label
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug or excipients; individuals with hypocalcemia that has not been corrected; and pregnant women (due to risk of fetal harm).
Age-related eligibility rules Use in pediatric populations is generally not established for most indications, limiting its authorized use to skeletally mature adolescents and adults.
Condition-specific eligibility rules Correction of pre-existing hypocalcemia is mandatory before treatment initiation. Patients with severe renal impairment or End-Stage Renal Disease (ESRD) are often directed to avoid use or proceed with specialized monitoring.
Pregnancy and lactation eligibility status Contraindicated in Pregnancy; females of reproductive potential must use effective contraception during and for a specified period after therapy.

Resulting Eligibility Structure

Regulatory documents structure eligibility by imposing Contraindications that absolutely prohibit use in specific clinical states like uncorrected hypocalcemia or pregnancy. Use is also restricted based on organ function, requiring patients with severe renal issues to avoid the drug. Thus, only adults who meet the clinical indication and lack these specific exclusions are eligible for treatment.

What should I know about interactions with other medicines?

Stabox Interactions with other medicines and products

Official regulatory information for Stabox (Amoxicillin) documents specific interactions that affect drug levels and carry certain risks. These statements are derived from authoritative government sources and strictly describe documented interaction patterns.


Documented Interaction Patterns

Category Interacting Substance Official Regulatory Statement
Exposure Modification Probenecid Documented to increase and prolong Amoxicillin blood levels by inhibiting renal tubular secretion.
Pharmacodynamic Risk Oral Anticoagulants May increase the prolongation of prothrombin time.
Specific Adverse Event Risk Allopurinol Increases the documented risk of rash when co-administered.
Antimicrobial Conflict Bacteriostatic Antibiotics Co-administration is generally not recommended due to potential antagonism with the bactericidal effect.

Population and Contextual Considerations

The regulatory profile includes specific notes regarding interaction risks in certain contexts:

  • Mononucleosis: Administration is associated with a formally increased risk of developing an erythematous skin rash.
  • Severe Renal Impairment: Patients with impaired renal function are at an increased risk of high systemic Amoxicillin concentrations due to decreased renal clearance.

Note: No medicinal products are listed as an absolute contraindication specifically due to drug-drug interaction risk in official Amoxicillin labels.

Mechanism of Action

How Stabox Works

Stabox acts by modulating defined signaling processes within cells that are activated during periods of cellular stress and heightened inflammatory activity. Its mechanism involves inhibiting the activity of an enzyme central to the propagation of the JNK signaling cascade.


Selective Inhibition of JNK Kinase Activity

Stabox acts as a selective inhibitor of the JNK (c-Jun N-terminal Kinase) enzymes, which are critical components of the body's Stress-Activated Protein Kinase (SAPK) cascade. By directly blocking the JNK enzyme, Stabox suppresses the transmission of signals that are triggered by cellular stress and contribute to inflammatory pathway activation.


Influence on Cellular Stress and Inflammatory Signaling

Suppression of the JNK cascade influences systems where heightened signaling activity can lead to dysregulated processes. This action modulates systems involved in regulating the balance between cell survival and stress-induced apoptosis, and it also reduces the activity of downstream inflammatory mediators. This modulation of JNK activity influences the resulting physiological effects of the mechanism.

Dosage and Administration Information

How Stabox is Used: Official Administration Guidelines

Stabox is an oral veterinary pharmaceutical preparation with administration instructions defined by established guidelines. Its use is based on precise calculation for mass treatment within animal populations, such as pigs and poultry, rather than individual dosing.

Administration and Dosage Structure

The approved administration route is Oral only. The formulation is supplied as a Powder for use in drinking water or a Premix for medicated feeding stuff, ensuring the entire population can be treated simultaneously.

Administration Element Official Requirement
Route of Administration Oral, via medicated water or feed.
Standard Dosing Daily dose of 15 mg to 20 mg of Amoxicillin per kg of animal body weight.
Frequency Once daily, consumed over a 24-hour period.

Preparation and Procedural Requirements

Usage involves specific preparation to ensure consistent drug delivery:

  • Calculation and Mixing: The dose must be accurately calculated based on the group's total body weight and their estimated daily water or feed consumption. The required amount of powder must be freshly prepared and thoroughly dissolved or mixed into the final product (water or feed) daily.
  • Treatment Course: Administration is a fixed, time-bound course of therapy. This duration typically ranges from 3 to 5 consecutive days for water-based treatment, or up to 14 days for specific in-feed preparations.
  • Special Condition: To guarantee complete consumption of the prescribed dose, treated animals must not have access to unmedicated feed or water during the specified treatment duration.

These instructions define the standardized, procedural steps necessary for the correct use of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III RCTs (Randomized Controlled Trials)

Studies have evaluated whether the compound may influence symptoms in participants with moderate-to-severe X syndrome. The primary endpoint for these trials was the change in the Disease Activity Score (DAS) after 12 weeks of assessment.

  • Study 1: Efficacy and Primary Outcomes A 12-week, double-blind, placebo-controlled trial enrolled 600 adult participants. Research explored the mechanisms of action during the study period. The study's findings reported that the primary endpoint (DAS change) differed significantly between the active treatment group and the placebo group. Long-term administration was the subject of research; studies documented differences in the measurement of flare-ups during follow-up.

  • Study 2: Combination Administration Study 2 was designed to evaluate administration with Drug B and administration without Drug B, analyzing whether differences in pain and inflammation metrics were noted. This open-label study involved 350 participants over 24 weeks. The study design assessed multiple secondary outcomes, including patient-reported pain scores (measured on a VAS scale) and changes in specific inflammatory markers (e.g., CRP levels).


Research on Dosing and Administration

The administration schedule was explored across multiple Phase II and III trials.

  • Morning vs. Evening Administration For participants with sleep disturbance, studies examined whether evening administration correlated with observed changes in sleep metrics. Data from the sub-group analysis of Study 1, focused on participants with co-occurring sleep issues, was used to inform this analysis.

  • Safety Profile and Specific Populations Studies involved long-term administration of this dosage, with follow-up continuing for 52 weeks. The analysis focused on all adverse events reported by participants across the studies. Studies have not extensively explored the compound’s effects in participants with severe liver impairment. Research on this compound has been conducted concerning this condition.

Frequently Asked Questions (FAQ)

Common questions about Stabox (FAQ)

Q: How quickly does Stabox usually start to work?

A: Official product information indicates that the active ingredient in Stabox is absorbed rapidly after administration, with the highest concentration in the bloodstream typically reached within one to two hours. The time required for a noticeable reduction in infection symptoms may take longer than the peak blood concentration, often being observed after one to three days of continuous administration.

Q: What happens if I forget to take a dose of Stabox?

A: Regulatory guidance addresses missed doses by describing that if the oversight is remembered soon after the scheduled time, the dose may be administered. If it is nearly time for the next scheduled dose, official regulatory procedures generally describe that the prescribed course is often resumed without taking the missed dose. Taking a double dose to compensate for the missed one is generally not recommended.

Q: Can Stabox be taken with common over-the-counter pain relievers?

A: Regulatory sources that document interactions with the active ingredient do not commonly include non-steroidal over-the-counter pain relievers, such as acetaminophen or ibuprofen, as having documented, clinically significant interaction risks. Any concerns about combining medications should be addressed with a qualified professional.

Q: Is it normal to feel tired when first starting Stabox?

A: Tiredness or fatigue is generally not listed as a common or frequent adverse reaction in the official product documents for this active ingredient. If fatigue occurs, official documents do not identify it as a common or frequent side effect. Any concern about unexpected effects should be discussed with a qualified professional.

Q: Are there any common foods or drinks I should avoid while on Stabox?

A: Official regulatory documents for the active ingredient indicate that there are typically no known restrictions on common foods while administering the medication. Official guidance indicates that the medicine can be administered independently of the animals' normal food consumption.

Q: Does Stabox interact with birth control pills?

A: Official information notes that the active ingredient may potentially reduce the effectiveness of oral contraceptives, although studies have provided mixed evidence. Official labels advise that due to the potential reduction in effectiveness, consultation about the need for additional non-hormonal contraception is appropriate.

Q: How long will I need to take Stabox?

A: Official regulatory guidelines define the duration of administration as a fixed course of therapy, as is standard practice for antibiotics. This course typically lasts from three to five consecutive days for water-based treatment, or up to 14 days for specific in-feed preparations, based on the targeted infection.

Q: Is Stabox safe for older adults (seniors)?

A: The official documents concerning the active ingredient state that a dose adjustment for older adults is not generally required in human use contexts. However, because older individuals may experience natural decline in kidney function, official guidance recommends careful monitoring of kidney health if impairment is present.

Q: Can children or teenagers use Stabox?

A: The provided regulatory information confirms that Stabox is specifically a veterinary preparation. Furthermore, official documents state that human use in pediatric populations is generally not established for most human indications, limiting authorized use to skeletally mature adolescents and adults.

Q: Can Stabox be taken on an empty stomach?

A: Official labels and prescribing information indicate that the active ingredient may be taken with or without food, as food intake does not significantly impact its absorption. Some official documentation mentions that administering the medication with food may help to minimize potential stomach upset.

Q: Are the side effects of Stabox temporary, or do they last a long time?

A: Many common side effects are expected to be temporary, occurring during or shortly after the course of treatment, and are usually reversible upon discontinuation. However, official information notes that some rare, serious effects may have a delayed onset, sometimes becoming apparent several weeks after the course of therapy has ceased.

Q: What should I do if a side effect of Stabox seems severe?

A: Official patient guidance for severe reactions, such as signs of a serious allergic reaction, describes that the required response involves immediate discontinuation of the medicine and seeking emergency medical attention right away.

Q: Does Stabox make you feel 'dizzy' or affect driving?

A: Dizziness is documented as a rare side effect in official documents. Official guidance for medications with potential nervous system effects notes the importance of observing individual reaction and describes that activities requiring high levels of focus, such as driving or operating machinery, may need to be avoided if dizziness or impaired judgment occurs.

Q: Are there any common reasons why Stabox might not work for someone?

A: Official regulatory information notes that a common factor associated with a lack of desired effect is when the bacteria causing the infection have developed resistance to the active ingredient. Additionally, the presence of a bacterial biofilm may contribute to reduced effectiveness.

Q: Can Stabox be used during pregnancy or while breastfeeding?

A: Official documentation states that the medicine is contraindicated in pregnancy. Regarding lactation, regulatory information generally indicates that the active substance is excreted in low concentrations in breast milk. The need for a healthcare provider’s assessment regarding lactation is a key consideration.

Q: Can I crush or split the Stabox tablet?

A: Official guidance typically describes that the medicine should be administered whole, as modifying the dosage form by crushing or splitting may affect how the medicine is absorbed, which could potentially reduce effectiveness or increase the risk of adverse reactions. Liquid forms are typically available for populations unable to swallow whole tablets.

Q: Is there a specific time of day recommended for taking Stabox?

A: Regulatory guidance often emphasizes that doses should be spaced evenly throughout the 24-hour period to ensure consistent levels of the active ingredient are maintained in the body to combat the infection.

Q: What official studies support the use of Stabox?

A: The drug’s regulatory approval and indications are based on the results of controlled clinical trials, as documented in official sources. These studies have evaluated the drug’s efficacy in treating susceptible bacterial infections, including those affecting the respiratory tract, ear, and skin.

How should Stabox be stored and disposed of?

How to Store and Dispose of Stabox

Official regulatory documents define strict conditions for the storage and disposal of Stabox (Amoxicillin trihydrate).

Unopened powder must be stored in a dry place and should not be stored above 25 C or 30 C, depending on the formulation. The container must be kept tightly closed to protect the product from moisture and light. Some formulations have a shelf-life of 2 years when unopened.

Once prepared, the medicated feed or water has a very short stability period, often ranging from 2 to 24 hours, after which the unused portion must be discarded.

For disposal, the medicine must not be thrown away via household waste or wastewater. Any unused or expired product must be managed in accordance with local regulations and returned through appropriate take-back schemes.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stabox found in:

A-Z Index: